In the last few years, the 340B program has received unprecedented scrutiny by Congress and the pharmaceutical industry. The Government Accountability Office (GAO) released a congressionally mandated report that called on the Health Resources and Services Administration (HRSA) to conduct audits of covered entities. HRSA is not only conducting audits of participating covered entities, it is clarifying program policy, focusing on additional program regulation, and publishing findings of audited entities. Pharmaceutical manufacturers continue to audit participating entities and invest in resources to increase entity audits. Attendees of this session will gain a better understanding of how to operate a compliant 340B pharmacy operation, including how to bring policy into practice in specific areas such as the Group Purchasing Organization (GPO) Prohibition. Participants will receive updates from key leaders regarding the latest integrity initiatives from HRSA’s Office of Pharmacy Affairs, its 340B Prime Vendor, and other 340B stakeholder representatives.